DLX-2270

DLX-2270 is an experimental serotonin receptor modulator which is under investigation for the potential treatment of schizophrenia.^[1]

DLX-2270

Clinical data
Other names	DLX2270
Routes of administration	Oral[1]
Drug class	Serotonin 5-HT2A receptor antagonist; Serotonin 5-HT2C receptor agonist; Antipsychotic; Psychoplastogen[1]
ATC code	None

It acts as a serotonin 5-HT_2A receptor antagonist and serotonin 5-HT_2C receptor agonist.^[1] In contrast to conventional antipsychotics, DLX-2270 is not a dopamine D₂ receptor antagonist.^[1] The drug is orally active and centrally penetrant.^[1] In preclinical research, DLX-2270 has psychoplastogenic effects.^[1] It reverses hyperlocomotion and social interaction deficits induced by the NMDA receptor antagonist phencyclidine (PCP).^[1] In contrast to serotonin 5-HT_2A receptor agonists, DLX-2270 does not produce the head-twitch response in rodents, and hence would not be expected to be hallucinogenic in humans.^[1]

DLX-2270 was first described in the scientific literature in 2025.^[1] It is under development by Delix Therapeutics.^[1] DLX-2270 is a small molecule, but its chemical structure does not yet appear to have been disclosed.^[1]

See also

• List of investigational hallucinogens and entactogens
• JRT
• Zalsupindole (DLX-001, AAZ-A-154)
• DLX-159
• Tabernanthalog (DLX-007)